Plus Net Income from 2010 to 2024
| PSTV Stock | USD 1.28 0.05 4.07% |
Net Loss | First Reported 2001-03-31 | Previous Quarter -2.9 M | Current Value -2.9 M | Quarterly Volatility 3.8 M |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 375.2 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.06, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Net Income |
Latest Plus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Plus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Plus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Plus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Plus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (13.32 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Plus Net Income Regression Statistics
| Arithmetic Mean | (19,402,120) | |
| Coefficient Of Variation | (49.82) | |
| Mean Deviation | 7,737,355 | |
| Median | (18,744,000) | |
| Standard Deviation | 9,666,305 | |
| Sample Variance | 93.4T | |
| Range | 35.3M | |
| R-Value | 0.40 | |
| Mean Square Error | 84.6T | |
| R-Squared | 0.16 | |
| Significance | 0.14 | |
| Slope | 862,973 | |
| Total Sum of Squares | 1308.1T |
Plus Net Income History
Other Fundumenentals of Plus Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Plus Therapeutics Net Income component correlations
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Net Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.3 M | -14 M | |
| Net Loss | -13.3 M | -14 M | |
| Net Loss | -23.3 M | -24.5 M | |
| Net Loss | (4.24) | (4.45) | |
| Net Income Per E B T | 0.92 | 0.97 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.